Director/PDMR Shareholding

Report this content

23 November 15:00 GMT

Transaction by Person Discharging Managerial Responsibilities

AstraZeneca PLC (the Company) announces that, on 22 November, it was notified of the following transactions in the Company's ordinary shares of $0.25 each (Ordinary Shares) by   Michel Demaré, Non-Executive Chair of the Board.

PDMR Position Nature of the transaction Date Quantity Price
Michel Demaré Non-Executive Chair of the Board Purchase of Ordinary Shares 21/11/2023 1,000 GB£101.05
Michel Demaré Non-Executive Chair of the Board Purchase of Ordinary Shares 22/11/2023 1,000 GB£101.70

Further details are set out in the attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation (since it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Michel Demaré
2 Reason for the notification
a) Position/status Non-Executive Chair of the Board
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name AstraZeneca PLC
b) LEI PY6ZZQWO2IZFZC3IOL08
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrumentIdentification code Ordinary Shares of US$0.25 each in AstraZeneca PLCGB0009895292
b) Nature of the transaction Purchase of AstraZeneca PLC Ordinary Shares of US$0.25
c) Price(s) and volume(s)
Price(s) Volume(s)
£101.05224 1,000
d) Aggregated information- Aggregated volume- Price Not applicable - single transaction
e) Date of the transaction 21 November 2023
f) Place of the transaction LON
1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Michel Demaré
2 Reason for the notification
a) Position/status Non-Executive Chair of the Board
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name AstraZeneca PLC
b) LEI PY6ZZQWO2IZFZC3IOL08
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrumentIdentification code Ordinary Shares of US$0.25 each in AstraZeneca PLCGB0009895292
b) Nature of the transaction Purchase of AstraZeneca PLC Ordinary Shares of US$0.25
c) Price(s) and volume(s)
Price(s) Volume(s)
£101.70 1,000
d) Aggregated information- Aggregated volume- Price Not applicable - single transaction
e) Date of the transaction 22 November 2023
f) Place of the transaction LON

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian Kemp
Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Subscribe

Documents & Links